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Severe tricuspid regurgitation (TR) is a complex condition of the right ventricle (RV) and 
tricuspid valve apparatus and is frequently associated with symptomatic heart failure 
and a significant morbidity and mortality. In these patients, left heart pathologies lead 
to chronic pressure overload of the RV, eventually causing progressive RV dilatation 
and functional TR. Therefore, TR cannot be considered as isolated heart valve disease 
pathology but has to be understood and treated as one component of a complex 
structural RV pathology and is frequently also a marker of an advanced stage of cardiac 
disease. In these patients, medical therapy restricted to diuretics and heart failure 
medication is frequently ineffective. Also, severe TR in the setting of advanced heart 
failure constitutes a high risk for cardiac surgery. Neither one of these treatment options 
has demonstrated a beneficial effect on long-term prognosis. The recent innovations 
in transcatheter technology led to efforts to develop interventional approaches to 
severe TR. Multiple innovative treatment concepts are currently under preclinical and 
clinical investigation to replace or repair TV function. However, up to date none of 
these approaches is established and there is still a lack of clinical data to support the 
efficacy of transcatheter TR treatment.
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1. inTRODuCTiOn
Severe tricuspid regurgitation (TR) is a complex condition of the right ventricle (RV) and tricuspid 
valve apparatus and is frequently associated with symptomatic heart failure and a significant 
morbidity and mortality (1, 2). In these patients, left heart pathologies lead to chronic pressure 
overload of the RV, eventually causing progressive RV dilatation and functional TR (3–7). Therefore, 
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treated as one component of a complex structural RV pathology 
and is frequently also a marker of an advanced stage of cardiac 
disease.
In these patients, medical therapy restricted to diuretics and 
heart failure medication is frequently ineffective. Also, severe TR 
in the setting of advanced heart failure constitutes a high risk for 
cardiac surgery (8–10). Neither one of these treatment options 
has demonstrated a beneficial effect on long-term prognosis. 
The recent innovations in transcatheter technology led to efforts 
to develop interventional approaches to severe TR. Multiple 
innovative treatment concepts are currently under preclinical 
and clinical investigation to replace or repair TV function (11–
17). However, there is still a lack of clinical data to support the 
efficacy of transcatheter TR treatment. Up to date, none of these 
approaches gained a CE mark or FDA approval and therefore 
they are only meant for investigational purposes.
2. AnATOMy OF THe TRiCuspiD vAlve 
AnD THe RigHT venTRiCle
The tricuspid valve anatomy is very complex and has a greater 
variability than the mitral valve. It is composed of the fibrous 
annulus, three leaflets, three papillary muscles, and the chordae 
tendineae. It is embedded in the right ventricular inflow tract 
in the junction between the right atrium (RA) and the right 
ventricle (RV). The elliptical shaped fibrous annulus is a three-
dimensional, highly dynamic structure. It is slightly larger and 
anatomically not as well defined as the mitral annulus. Its size 
and shape changes during the cardiac cycle due to contraction of 
the surrounding myocardium (18). The annulus provides a base 
for the prominent anterior, the septal and a mostly hypoplastic 
posterior leaflet. Valve calcification is a pathologic process 
but the valves are less prone to calcification compared to the 
mitral valve even at an advanced disease state and age. During 
right ventricular contraction, the annular area decreases by 
approximately 25–30%, which is essential for leaflet coaptation 
and competence of the valve (19–21). Thus, any conditions 
altering geometry of the tricuspid valve apparatus - such as 
changing loading conditions or structural enlargement of 
the right-sided chambers - negatively impact valve function. 
Adjacent to the attachment of the septal leaflet there is the 
AV-node and the right coronary artery encircles the valve.
3. epiDeMiOlOgy AnD pROgnOsTiC 
iMpACT OF TR
TR (TR) is a common insufficiency typically graded in mild, 
moderate and severe TR. While mild TR is frequently observed 
in asymptomatic persons, moderate and severe TR are seen less 
often (22). As even with pronounced TR many patients remain 
asymptomatic for several years the assessment of prevalence 
is difficult. In the US population, moderate-to-severe TR was 
estimated at approximately 1.6 million cases (23, 24).
However, as TR frequently develops with the progression of 
left heart or pulmonary disease, the underlying disorder rather 
than the tricuspid valve lesion tends to dominate the clinical 
picture. Increased right atrial pressure is transmitted to the 
central and hepatic veins leading to hepatosplenomegaly and 
ascites, which are present in 90% of patients with severe TR 
(23, 24).
Nath et. al conducted an echocardiographic series of 5,223 
patients. Moderate to severe TR was found in 16% of patients 
(1). With increasing severity of TR mortality increased. The poor 
prognosis of the severe TR is independent of left ventricular 
ejection fraction and pulmonary hypertension (1). Several more 
recent studies confirmed these results and therefore underlined 
the correlation between severity of TR and increased mortality 
(25–29). In addition, patients with severe symptomatic TR showed 
prolonged hospitalization and a higher rate of rehospitalization 
(26).
4. pATHOpHysiOlOgy
TR is most frequently “functional” in nature (8). It is commonly 
observed in patients with left heart valve disease, myocardial 
disease or pulmonary hypertension. A volume overload or/and 
elevated RV pressure leads to a right ventricular (RV) remodeling 
with RV enlargement followed by a tricuspid annulus dilatation. 
An increase in TV annular area develops primarily due to 
dilatation of the posterior and lateral segments along the right 
ventricular free wall (30, 31). Another mechanism of functional 
TR if an impaired leaflet function e.g., as in the presence of a 
lead crossing the TV.
In early stages RV and annulus dilatation can still be 
compensated and TR is not severe. A progressive dilatation leads 
to papillary muscle displacement and tethering of the leaflets 
causing severe TR. Regurgitation volume leads to increased 
diastolic loading which supports further RV and annulus 
dilatation entering a vicious circle Because right ventricular 
stroke volume is partially expelled backwards into the venous 
system, there is a resulting decrease in cardiac output and RV 
afterload. This decrease in right ventricular afterload in presence 
of TR may initially actually mask a decreased RV contractility. 
As right ventricular preload rises the right ventricle loses its 
contractility and eventually fails. As the tricuspid valve loses it 
function, hemodynamic parameters of the right atrium adjust 
to those in the right ventricle called a ventricularisation of the 
right atrium and finally there is a systolic backflow in the hepatic, 
abdominal and peripheral veins too.
Primary or non-functional TR is seen less frequent. It 
occurs when there is damage to the tricuspid leaflets, chordae, 
papillary muscles, or annulus, independent of right ventricular 
dysfunction or pulmonary hypertension. It can be caused 
by infective endocarditis, congenital disease like Ebstein 
anomaly or atrioventricular canal, rheumatic fever, carcinoid 
syndrome, endomyocardial fibrosis, myxomatous degeneration 
of the tricuspid valve leading to prolapse, penetrating and non-
penetrating trauma, and iatrogenic damages during cardiac 
surgery, biopsies, and catheter placement in right heart chambers 
Beckhoff et al.
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Echocardiography is the main tool to confirm the diagnosis, 
determine aetiology and assess the severity of TR. Color flow 
imaging can be used as a screening method. Grading of the severity 
should be performed in accordance to the guidelines published in 
2010 by the European Society of Echocardiography and in 2017 by 
the American Society of Echocardiography (32, 33).
These guidelines recommend several structural, qualitative, 
semiquantitative and quantitative parameters (Table  1). A 
simple parameter that is easy to obtain and well validated 
is the vena contracta width (VCW). It is usually obtained in 
the four-chamber view using color flow imaging. The VCW 
is measured perpendicular to the commissural line at the 
narrowest portion of the jet reflecting the regurgitant orifice 
area. A VCW > 7 mm indicates a severe TR. Lower values 
are difficult to interpret and therefore should not be used 
to distinguishing moderate from mild or severe TR. Using a 
continuous wave (CW) Doppler in the four-chamber view at 
the tricuspid leaflet tips the TR can be further evaluated. In 
case of a severe TR the WC signal is intense, truncated and 
triangular indicating an elevated right atrial pressure. The peak 
E velocity representing the early diastolic filling increases in 
the proportion to the degree of TR. A peak E Velocity >1 m/s 
suggests a severe TR. The proximal isovelocity surface area 
(PISA) is measured in the apical four chamber view and in the 
parasternal long axis. Nyquist limit must be lowered to 28 cm/s. 
PISA radius is than measured using the first aliasing. A PISA 
radius >9 mm indicates a severe TR whereas a radius <5 mm 
indicates a mild TR. After calculating the PISA the effective 
regurgitant orifice area (EROA) and regurgitations volume 
(Rvol) can be calculated using the time velocity integral in the 
continuous wave Doppler (CW) signal. An EROA ≥40 mm2 
or a Rvol ≥45 mL indicates severe TR.
In moderate to severe TR evaluation of the RV and RA 
dimensions, RV function and the venous congestion is mandatory. 
The tricuspid annular plane systolic excursion (TAPSE) is easy 
to obtain and well validated to assess the right heart function. A 
TAPSE <17 mm is highly suggestive of RV systolic dysfunction.
The right heart dimensions have previously been published 
in an update from the American Society of Echocardiography 
and the European Association of Cardiovascular Imaging (34). 
Measurements should be performed in multiple acoustic windows 
but the most important view is the four-chamber view focused on 
the RV. In this view, the left apex is in the center of the scanning 
sector and the largest basal RV diameter is displayed. In this view, 
a diameter >41 mm at the base and >35 mm at the midlevel in 
the RV-focused view indicates RV dilatation. The RV longitudinal 
diameter ranges between 59–83 mm, and therefore a dilatation 
is present if the longitudinal diameter exceeds 83 mm. Normal 
diastolic tricuspid valve annulus diameter is 22–33 mm and a 
significant annulus dilatation is present when the diameter exceeds 
21 mm/m2 (>40 mm).
The right atrium is assessed in the same echocardiographic 
window. Mostly performed are linear and volume measurements. 
Linear measurements include the minor and the major axis of the 
LA. The minor axis is should be measured as the distance between 
the lateral RA wall and interatrial septum in the midatrial level. 
A normal value is 1.9 cm/m2. The major axis is orthogonal to the 
minor axis and is normally between 2.4–2.5 cm/m2. The more 
accurate RA volume is 21–25 mL/m2.
TABle 1 |  Grading the severity of TR.
Mild Moderate severe
structural
Tv morphology Normal or mildly abnormal leaflets Moderately abnormal leaflets
Flail leaflet, large coaptation defect, severe retraction, 
large perforation
Rv size Normal Normal or mild dilatated Dilatated
RA size Normal Normal or mild dilatated Dilatated
vCi diameter (cm) <2 2–2,5 >2
Qualitative Doppler
Color flow jet area Small, narrow, central Moderate central jet Very large central jet or eccentric wall impinging jet
Flow convergence zone Not existent Intermediate in size and duration Large throughout systole
Cw signal of jet Faint/partial/parabolic Dense, parabolic or triangular
Dense, triangular with early peaking (peak ,2 m/s in 
massive TR)
semiquantitative
Color flow jet area (cm2) Not defined Not defined >10
vCw (cm) <0.3 0.3–0.69 ≥0.7 
pisA radius (cm) ≤0.5 0.6–0.9 >0.9 
Hepatic vein flow Systolic dominance Systolic blunting Systolic flow reversal
Tricuspid inflow A-wave dominant A-wave dominant E-wave >1.0 m/sec
Quantitative
eROA (cm2) <0.20 0.20–0.39 ≥0.40
R vol (ml) <30 30–44 ≥45
Based on the 2010 guidelines by the European Society of Echocardiography and the 2017 guidelines by the American Society of Echocardiography (32, 33).
CVI, vena cava inferior; CW, continuous-wave; EROA, effective regurgitant orifice area; R Vol, regurgitant volume; RA, right atrium; RV, right ventricle; TR, tricuspid regurgitation; 
TV, tricuspid valve; VCW, vena contracta with.
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The atrial pressure can be estimated by the use of vena cava 
diameter and the percentage of decrease of diameter during 
inspiration. An IVC diameter <2.1 cm with a collapse >50% during 
inspiration suggests normal RA pressure of 3 mm Hg, whereas 
IVC diameter >2.1 cm that collapses <50% during inspiration 
suggests high RA pressure of 15 mm Hg (35). In cases where IVC 
diameter and collapse do not fit this paradigm, an intermediate 
value of 8 mmHg should be assumed (34). Hepatic veins are an 
additional tool grading the TR. Using color flow or pulsed wave 
Doppler (PW) a systolic flow reversal can be observed in patients 
with severe TR.
6. CuRRenT THeRApy AnD iTs 
liMiTATiOns
6.1. Currently Recommended Treatment 
and Their indications
Currently medical and surgical therapy are the only established 
treatments options for patients with severe TR. Medical treatment 
is considered a symptomatic therapy limited to diuretics. Surgical 
repair or replacement is associated with a significant mortality and 
is therefore restricted to a selected group of patients with a suitable 
risk profile. Also, the timing for surgery remains controversial (36). 
According to the ESC/EACTS guidelines, patients with primary 
TR should undergo surgery even when still asymptomatic or 
when undergoing surgery for left-sided valvular heart disease. In 
contrast, secondary severe TR is only surgically corrected when 
patients undergo left-heart surgery. However, these guideline 
recommendations are Level C recommendations due to the lack 
of data. Although these patients respond well to diuretic therapy 
medical treatment should not delay surgery to avoid secondary 
damage in terms of irreversible RV dysfunction which is associated 
with worse outcome.
6.2. surgical Therapy
Today surgical correction of TR focuses on restoring valve 
function by reducing annular size. However, the efforts to 
achieve the most durable results have resulted in an ongoing 
debate as to whether annular plication should be achieved by 
implanting either flexible or rigid rings rather than by means of 
a partial purse string suture technique (“DeVega-technique”). 
Rigid annuloplasty rings appear to have a lower incidence of 
recurrent TR than flexible devices or the DeVega technique. 
In addition, the edge-to-edge tricuspid valve repair has been 
suggested as providing an effective adjuvant procedure for severe 
residual TR following annuloplasty (37, 38). The procedure is 
analogous to mitral valve repair by leaflet approximation and 
involves anchoring the anterior leaflet to the facing edges of the 
septal and posterior leaflets of the tricuspid valve, thus creating a 
triple orifice. Prosthetic TV replacement is reserved for advanced 
structural valve disease and carries a higher perioperative risk 
compared to valve repair. Following tricuspid valve replacement, 
a lower 10 year survival rate has been reported compared to TV 
replacement (37–4.8% versus 47.5–3.5%) (39).
6.3. Current interventional Approaches
Patients with severe TR are frequently considered inoperable due 
to comorbidities and surgery is therefore often refused (40, 41). 
Thus, there is a large unmet need for less invasive treatment options. 
Recently, the tricuspid valve is receiving much attention from 
interventional cardiologists and industry, seeking to develop novel 
catheter-based approaches to TR. So far most of these treatments 
have been applied in compassionate human cases or small 
feasibility trials and limited experimental data have been published. 
Transcatheter TR repair concepts are focusing to reproduce 
surgical concepts such as annuloplasty or leaflet adoption, but also 
alternative approaches are under investigation such as coaptation 
enhancement or heterotopic caval valve implantation (Figure 1).
FiguRe 1 |  Overview over new tricuspid valve repair devices. CAVI, caval valve implantation; TV, tricuspid valve; TRAIPTA, transatrial intrapericardial tricuspid 
annuloplasty.
Beckhoff et al.
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6.3.1. Leaflet Enhancement
6.3.1.1. The FORMA Device (Edwards Lifesciences)
The FORMA Repair System (Edwards Lifesciences) has been 
designed for patients with a severe functional TR. Annulus 
dilatation leads to malcoaptation of leaflets and therefore to a 
central regurgitant jet. By advancing a spacer in the center of the 
regurgitant yet the regurgitant orifice area is occupied and leaflets 
have a new coaptation surface. Therefore, the TR Grade can be 
reduced. The spacer is a foam-filled polymer balloon that passively 
expands via holes in the spacer shaft. It is available in 12 and 15 
mm both with a length of 42 mm. Two radiopaque markers help 
to initially position the spacer using fluoroscopy. The distal end 
is connected to a rail anchored at the apex of the RV whereas the 
proximal end is locked in the subclavian region with the extra rail 
length coiled into a pre-pectoral pocket.
The first in men experience with the FORMA device was 
published in 2015. Seven high-risk patients with severe TR 
presenting with clinical signs of heart-failure deemed unsuitable 
for surgery received the FORMA device as a compassionate 
use. All patients had a New York Heart Association (NYHA) 
functional class II to IV. Device implantation was successful 
without procedural complications in all patients. Severity of TR 
could be reduced significantly to moderate TR in 3 patients and 
to mild TR in 4 patients. At 30 day follow-up, all patients but 1 
demonstrated an improvement in NYHA functional status to class 
II. No complications related to the device or vascular access were 
observed during follow-up (42). Recently the one-year experience 
from eighteen patients at 3 centers in Canada and Switzerland with 
the transcatheter FORMA system was published. They presented a 
good mid-term safety profile. Despite variable success in reducing 
echocardiographic TR grade, there were significant clinical 
improvements and reductions in right ventricular dimensions (43).
The FORMA system is an investigational device and not for sale in 
any country. An Early Feasibility Study is currently recruiting patients 
in the USA (NCT02471807). The 30 day data of the US feasibility trial 
were presented at the TCT 2017 by Susheel Kodali, MD (NewYork-
Presbyterian/Columbia University Medical Center, New York, NY). 30 
patients with severe symptomatic TR from five US centers underwent 
implantation of the Forma device. All in all, the results proved that the 
device is a feasible therapy for patients with severe TR. Nevertheless, 
it was associated with infrequent distal anchor dislodgements and the 
complications thereof. The next generation of this device probably 
with a more predictable anchor capture without dislodgement or RV 
perforations is already under development.
Beside the Early Feasibility Study in the USA other multicenter 
trials are planned in Europe and Canada.
6.3.1.2. MitraClip in Tricuspid Position
The MitraClip® system has been invented for high risk patients with 
mitral regurgitation which are unsuitable for surgery. It is a procedure 
that involves the percutaneous implantation of one or more clips 
grasping and approximating the edges of the leaflets at the origin of 
the regurgitant jet and therefore reducing it. In 2011, this procedure 
was presented first time by Feldman et al (44). Until today this has now 
been integrated in the clinical routine for patients with severe mitral 
regurgitation at high risk constellation. In 2016, the first clips could 
successfully be implanted at the tricuspid valve (45). In 2017, Nickenig 
et al demonstrated the feasibility and safety of leaflet coaptation using 
the MitraClip in tricuspid position in 64 consecutive patients (46). 
In this report clips where implanted in multiple commissural sites, 
while now the strategy is to perform a bicuspidization of the tricuspid 
valve by a progressive clipping of the septal and anterior leaflet until 
satisfactory reduction of TR is achieved as well as the gradient across 
the valve is not increased significantly.
Nevertheless, clipping the tricuspid valve is more difficult than 
performing a clip in mitral position. The angle between the IVC 
and the TV annular plane makes coaxial positioning difficult. A 
transjugular approach has been described but the femoral approach 
was favored in the above-mentioned study.
6.3.2. Annuloplasty
6.3.2.1. Trialign
The Trilign device (Trialign, Tewksbury, Massachusetts) is a 
percutaneous minimal invasive annuloplasty system initially designed 
for the treatment of symptomatic functional mitral regurgitation. First 
experiences have been made with the treatment of patients with severe 
tricuspid regurgitation. It was inspired by the Kay bicuspidization 
procedure, in which the annulus is plicated along its muscular 
part adjacent to the posterior leaflet (47). With the help of an 8 F 
articulating wire delivery catheter and a pledget delivery catheter 
using a transjugular venous approach, pledgets with sutures are fixed 
at the anteroposterior and septoposterior commissures. These steps 
are guided by TEE and fluoroscopy. Afterwards a plication lock device 
is used to bring the 2 pledgeted sutures together, plicating the annulus 
and effectively bicuspidizing the tricuspid valve.
The first-in-man procedure was published in 2015. The Trialign 
device was implanted in an 89-year-old woman with right heart 
failure due to TA dilation and severe TR as a compassionate use. 
After procedure, there was a significant reduction of tricuspid 
annulus area (57%) and effective regurgitant orifice area (53%). 
Hemodynamic parameters in terms of right atrial pressure and left 
ventricular stroke volume also improved (48). There are two ongoing 
early feasibility studies, one in the USA (NCT02574650) and one 
in Europe (NCT03225612). The 30 day results of early feasibility 
trial in the USA were recently published. The results confirmed the 
safety of the novel transcatheter device, which reduced tricuspid 
annulus diameter, effective regurgitant orifice area, increased 
the left ventricular stroke volume, and improved quality-of-life 
measurements (49).
6.3.2.2. TriCinch
The TriCinch System (4Tech Cardio Ltd., Galway, Ireland) is a 
percutaneous device designed to reduce functional TR by reducing 
the septo-lateral distance. It is composed of two parts: a stainless-
steel corkscrew and a self-expanding nitinol stent. Both are 
connected by a Dacron band. First, the corkscrew is delivered by 
a delivery system from the Inferior Vena Cava and fixated at the 
anteroposterior TV annulus. After the delivery system is removed 
a second delivery system is advanced containing the other half of 
the TriChinch System. Both Dacron bands are now connected with 
a locking mechanism. By pulling the TriChinch System tension 
is applied to the TVA and therefore the septo-lateral distance is 
6 May  2018 | Volume 5 | Article 49Frontiers in Cardiovascular Medicine | www. frontiersin. org
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reduced. If echocardiography shows the desired reduction of TR, 
the stent is deployed in the inferior vena cava to maintain the 
tension.
Four stent sizes are currently available (27, 32, 37, and 43 mm).
The “first-in-man” procedure was reported in 2015. The patients 
was a 72-year-old woman enrolled in the PREVENT (Percutaneous 
Treatment of Tricuspid Valve Regurgitation With the TriCinch System; 
NCT02098200) study. She had a severe functional TR associated with 
tricuspid annular dilation causing multiple hospitalization. New 
York Heart Association functional class was III. The procedure was 
completed in 56 min and the patient was discharged 5 days later. 
No intra- or postprocedural complications were observed. TR grade 
could be reduced from grade 4 to grade 3. The 6 month follow-up 
showed an improved quality of life.
At this time, enrollment of 24 patients in the PREVENT Trial 
is completed. Results are not published yet.
6.3.2.3. TRAIPATA
The transatrial intrapericardial tricuspid annuloplasty 
(TRAIPTA) is a minimal invasive device for patients with 
functional TR. Once implanted it acts as a epicardial annuloplasty 
band. After a transfemoral venous approach pericardial access is 
obtained by puncturing the right atrial appendage.
Once the delivery device is advanced in the epicardial space it 
opens a preformed loop that is passed around the apex of the heart 
and then retracted toward the base. Finally it can be tightened at 
the atrioventricular groove. After the procedure, the right atrial 
appendage must be closed with a percutaneous occluder device.
The device has not yet been implanted in humans but it was applied 
in 16 Yorkshire swines, including 4 with functional TR. Tricuspid 
septal-lateral and anteroposterior dimensions, the annular area and 
perimeter was significantly reduced. Small postprocedural effusions 
(mean, 46 ml) resolved completely at follow-up. There is no other 
trial registered at Clinical Trials.
6.3.2.4. Cardioband
The Cardioband repair system (Edwards Lifesciences) is an approved 
treatment of secondary (functional) mitral regurgitation (FMR). 
It has been recently used in a clinical trial in patients with severe 
tricuspid regurgitation caused by a dilatation of the right annulus. 
The cardioband system is a catheter-based device that functions as 
a percutaneous annuloplasty band using a transfemoral approach. 
Implantation of the Cardioband is performed by stainless steel 
anchors (6 mm long). After cinching of the Cardioband the device 
reduces the tricuspid annular dimensions. Studies are currently 
investigating the use of the Cardioband in tricuspid regurgitation 
(NCT02981953, NCT03382457).
6.3.2.5. Millipede IRIS Transcatheter Annuloplasty Ring
The IRIS is a complete semi-rigid annuloplasty ring that is placed via 
a transfemoral venous approach. After puncture of the femoral vein 
a delivery catheter is advanced into the right atrium. The delivery 
catheter places the device supra-annularly and the ring is then 
anchored and cinched reducing annular size and therefore valvular 
regurgitation. Up to date annuloplasty device is only studied in 
patients with mitral regurgitation (NCT02607527).
6.3.3. Valve Replacement
6.3.3.1. Orthotopic Valve Replacement
The tricuspid annulus is a complex and highly dynamic structure 
offering little resistance for long-term fixation of orthotopic valves. 
Particularly under conditions of severe TR the annulus is massively 
dilated with a loss of anatomic landmarks. Therefore, the development 
of transcatheter orthotopic valve implantation is associated with 
specific challenges, including device fixation, paravalvular sealing, 
sizing and thrombogenicity in a low-flow, low-pressure circulation. 
The NaviGate transcatheter tricuspid valve has been developed for 
orthotopic correction of severe functional TR by “NaviGate Cardiac 
Structures Inc.. The bioprosthetic self-expanding valve with a size 
of up to 52 mm has been implanted successfully in compassionate 
cases (50).
6.3.3.2. Heterotopic Valve Replacement
Severe TR leads to a systolic backflow in the hepatic, abdominal and 
peripheral veins causing peripheral oedema, liver cirrhosis, ascites 
and gastrointestinal dysfunction. Implanting a prosthetic valve in the 
central venous system (caval valve implantation = CAVI) reduces the 
venous congestion leading to amelioration of peripheral signs of right 
heart failure (51). Heterotopic valve implantation can be performed as 
single valve in the IVC or as dual valve in the IVC and SVC. The major 
challenges to valve implantation are the variable and large diameter of 
the vena cava inferior and superior and the short distance between the 
right atrium to the hepatic veins. “First-in-man” implantation of a self-
expanding customized prosthetic valve in the IVC was reported in 
2011 (51). The patient was a 79-year-old female with severe functional 
TR considered inoperable due to multiple previous open-heart 
surgeries. The patient had suffered from progressive symptoms of 
RV congestion with peripheral oedema, liver cirrhosis, and persistent 
ascites with gastrointestinal dysfunction. Procedure was performed 
under general anesthesia in a hybrid operating room. The prosthetic 
valve was delivered from the right femoral vein with a custom-made 
27 F implantation catheter. After satisfactory position was confirmed 
by fluoroscopic and echocardiographic visualization valve was 
released from catheter. There were no intra- and postprocedural 
complications. After deployment, excellent function of the device 
was observed and echocardiography showed a nearly abolished 
ventricular wave after valve deployment. During follow-up the patient 
experienced a gradual improvement of symptoms related to venous 
congestion and right heart failure. Despite the promising data from 
compassionate use of the CAVI procedure data demonstrating clinical 
efficacy is still lacking. A recent observational trial in 25 patients 
demonstrated the safety and hemodynamic efficacy of CAVI using 
either the IVC-only or the BiCAVI approach (52). For CAVI only a 
few valves are suitable. The percutaneous valve system (Tric Valve, 
P&F GmbH, Vienna, Austria) has been developed for the bicaval 
venous implantation (Figure 2). It is composed of two separate three 
leaflet pericardial tissue valves reaching from 28 to 43 mm. Beside 
the Tric Valve balloon-expandable valves (BEV) like the commercial 
available Edwards Sapien XT and Sapien 3 can be used. These valves 
are designed for treatment of aortic stenosis (29 mm Edwards Sapien 
XT or Sapien 3; Edwards Lifesciences, Irvine, CA), but there is a 
growing experience in the off-label use of these devices for treating 
severe TR. Because of the large diameter of the cavoatrial junction, 
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SVC and IVC position has been used for CAVI. (B, D, e) An angiogram of the right atrium and transesophageal echo demonstrates function of both valves. 
(C) Position of both valves is visualized by CT.
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